Relafen 750, pharmacologically known as its salt potassium, presents a compelling case from a biochemical approach. Its effect primarily involves the inhibition of cyclooxygenase catalysts , specifically COX-2, producing a reduction in prostaglandin synthesis . This process effectively reduces so